argenx NV ADR (ARGX)vsCatalyst Pharmaceuticals Inc (CPRX)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
CPRX
Catalyst Pharmaceuticals Inc
$23.80
+3.16%
HEALTHCARE · Cap: $2.84B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 619% more annual revenue ($4.24B vs $588.99M). CPRX leads profitability with a 36.4% profit margin vs 30.5%. CPRX trades at a lower P/E of 13.7x. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
CPRX
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
-109.5%
Fair Value
$11.42
Current Price
$23.80
$12.38 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 40.5%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Attractively priced relative to earnings
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Weak financial health signals
Earnings declined 6.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : CPRX
The strongest argument for CPRX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 36.4% and operating margin at 40.5%.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : CPRX
The primary concerns for CPRX are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CPRX is a mature play — different risk/reward profiles.
CPRX carries more volatility with a beta of 0.71 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 59/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Catalyst Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?